The observation from preclinical and translational data that the effect of BRAF and MEK inhibitors on the tumour microenvironment is dynamic and temporally dependent raises the possibility that sequential administration of BRAF/MEKi and CPI could optimise anti-tumour immunogenicity. The gene discussed is BRAF; the disease is neoplasm.